Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by resolving/curing bacterial infections in patients with diabetic foot ulcersRECCE® 327 dosed daily or every second day for 14 days is considered to be safe and well-toleratedAdditional clinical sites to be launched in Australia, and additional clinical trials will be launched internationally in diab
Source: yahoo.com
